Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2338803
Max Phase: Preclinical
Molecular Formula: C12H10F2N2O2
Molecular Weight: 252.22
Molecule Type: Small molecule
Associated Items:
ID: ALA2338803
Max Phase: Preclinical
Molecular Formula: C12H10F2N2O2
Molecular Weight: 252.22
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=c1[nH]nc(CCc2cc(F)cc(F)c2)cc1O
Standard InChI: InChI=1S/C12H10F2N2O2/c13-8-3-7(4-9(14)5-8)1-2-10-6-11(17)12(18)16-15-10/h3-6H,1-2H2,(H,15,17)(H,16,18)
Standard InChI Key: BLEWCUQOJLGDAH-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 252.22 | Molecular Weight (Monoisotopic): 252.0710 | AlogP: 1.54 | #Rotatable Bonds: 3 |
Polar Surface Area: 65.98 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 7.08 | CX Basic pKa: | CX LogP: 2.02 | CX LogD: 1.53 |
Aromatic Rings: 2 | Heavy Atoms: 18 | QED Weighted: 0.87 | Np Likeness Score: -0.86 |
1. Hondo T, Warizaya M, Niimi T, Namatame I, Yamaguchi T, Nakanishi K, Hamajima T, Harada K, Sakashita H, Matsumoto Y, Orita M, Takeuchi M.. (2013) 4-Hydroxypyridazin-3(2H)-one derivatives as novel D-amino acid oxidase inhibitors., 56 (9): [PMID:23566269] [10.1021/jm400095b] |
2. Zimmermann SC, Rais R, Alt J, Burzynski C, Slusher BS, Tsukamoto T.. (2014) Structure-Metabolism Relationships in the Glucuronidation of d-Amino Acid Oxidase Inhibitors., 5 (11): [PMID:25408840] [10.1021/ml500335z] |
3. Hin N, Duvall B, Ferraris D, Alt J, Thomas AG, Rais R, Rojas C, Wu Y, Wozniak KM, Slusher BS, Tsukamoto T.. (2015) 6-Hydroxy-1,2,4-triazine-3,5(2H,4H)-dione Derivatives as Novel D-Amino Acid Oxidase Inhibitors., 58 (18): [PMID:26309148] [10.1021/acs.jmedchem.5b00482] |
4. Hin N, Duvall B, Berry JF, Ferraris DV, Rais R, Alt J, Rojas C, Slusher BS, Tsukamoto T.. (2016) D-Amino acid oxidase inhibitors based on the 5-hydroxy-1,2,4-triazin-6(1H)-one scaffold., 26 (8): [PMID:26965861] [10.1016/j.bmcl.2016.02.068] |
5. (2015) Dihydroxy aromatic heterocyclic compound, |
6. (2016) Pyridazinone compounds and their use as DAAO inhibitors, |
Source(2):